Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC
Over the last decade, the revolution in genomic medicine and immunotherapy has led to a rapid expansion of the therapeutic landscape in advanced non-small cell lung cancer (NSCLC). This progress is now slowly starting to reach those with earlier stage NSCLC, including localised stage I –II disease and locally advanced stage III disease. Unlike other early-stage diseases, including breast and colon cancer, the prognosis in NSCLC is poorer and many patients experience relapse. Despite curative-intent therapy, over 20% of patients with stage I NSCLC, 50% with stage II, and a stagge ring 60% with stage IIIA are dead within 5 years of curative-intent therapy [1].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Alex Friedlaender, Jarushka Naidoo, Giuseppe Luigi Banna, Giulio Metro, Patrick Forde, Alfredo Addeo Source Type: research
More News: Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Immunotherapy | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer